|
Dallas–Fort Worth, TX Press Releases
|
(Dallas.CityRegions.Com, May 11, 2018 ) Orbis Research has announced the addition of the “Global Non-Hodgkin Lymphoma Therapeutics Market-Growth, Trends and Forecasts (2018-2023)” to store by company, by country, and by application/type for the competitive landscape analysis. The study of Global Non-Hodgkin Lymphoma Therapeutics Market-Growth, Trends and Forecasts (2018-2023) provides the market size information, In-Depth Analysis along with Competitive Insights and Segmentation.
Get Sample Report @ http://orbisresearch.com/contacts/request-sample/2126780
Non-Hodgkin Lymphoma Therapeutics Market The global Non-Hodgkin Lymphoma Therapeutics Market has been estimated to reach USD 7.45 billion in 2023. The market is expected to register a CAGR of 7.4% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.
Increase in public awareness about NHL and robust drug pipeline for the treatment of NHL Increase in public awareness about NHL and robust drug pipeline for the treatment of NHL is driving the market. Improved diagnostic techniques to detect NHL is positively affecting the market. In addition, increase in prevalence of non hodgin lymphoma is also fuelling the NHL therapeutics market across the globe.
High cost of NHL drugs and side-effects associated with them High cost of NHL drugs and various complications associated with it is acting as a restraint for non-hodgkin lymphoma therapeutics market. Additionally, increasing rituximab resistance, along with the stringent regulatory guidelines are restraining the growth of the market.
North America to dominate the market The Non-Hodgkin Lymphoma Therapeutics market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America. North America dominates the non-hodgkin lymphoma therapeutics market due to the increasing technological advancements and the rising incidence of NHL in the country. Asia-Pacific is also expected to propel the non-hodgkin lymphoma therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing prevalence of NHL.
Key developments in the market In August, 2017 Gilead Sciences, Inc. and Kite Pharma, Inc. announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $11.9 billion. Kite’s most advanced therapy candidate, axicabtagene ciloleucel, is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma. In November, 2017, U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) from AstraZeneca for treating adults who have an aggressive form of non-Hodgkin lymphoma called mantle cell lymphoma that has progressed despite at least one prior treatment.
Major key players: F. HOFFMAN LA-ROCHE LTD., JOHNSON & JOHNSON, MERCK, BRISTOL MYERS SQUIBB CO., CELGENE CORP, ELI LILLY AND CO., GLAXOSMITHKLINE PLC and BAYER AG etc.
Reasons to purchase this report Market analysis for the Global Non-Hodgkin Lymphoma Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale. Analyzing various perspectives of the company with the help of Porter’s five forces analysis The treatment type that is expected to dominate the market Regions that are expected to witness fastest growth during the forecast period Identify the latest developments, market shares and strategies employed by the major market players. 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the report This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
Companies Mentioned: F. HOFFMAN LA-ROCHE LTD., PFIZER, MERCK, BRISTOL MYERS SQUIBB CO., NOVARTIS, GLAXOSMITHKLINE PLC, BAYER AG
Enquiry About Report @ http://orbisresearch.com/contacts/enquiry-before-buying/2126780
Some of Major Point From TOC
1. INTRODUCTION 1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW 5.1 CURRENT MARKET SCENARIO 5.2 PORTER’S FIVE FORCES 5.2.1 BARGAINING POWER OF SUPPLIERS 5.2.2 BARGAINING POWER OF CONSUMERS 5.2.3 THREATS OF NEW ENTRANTS 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC) 6.1 MARKET DRIVERS 6.1.1 INCREASING FOCUS ON PRECISION MEDICINE 6.1.2 INCREASING INCIDENCE OF BRAIN CANCER 6.2 MARKET RESTRAINTS 6.2.1 VERY FEW BRAIN CANCER SPECIFIC DRUGS 6.2.2 HIGH COST OF TREATMENT 6.3 OPPORTUNITIES 6.4 KEY CHALLENGES Continue...
Browse Full Report @ http://www.orbisresearch.com/reports/index/global-non-hodgkin-lymphoma-therapeutics-market-growth-trends-and-forecasts-2018-2023
About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817; +912064101019 Email ID: sales@orbisresearch.com
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com
|
|
|
|